Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis
- 1 January 1990
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 12 (1) , 25-33
- https://doi.org/10.1185/03007999009111488
Abstract
SummaryThe efficacy and tolerability of clarithromycin and erythromycin stearate in the treatment of documented Group A beta-haemolytic streptococcal pharyngitis were compared in a single-centre, open, out-patient study. One hundred and twenty patients were randomly assigned to each treatment group. Dosage of clarithromycin and erythromycin was 250 mg twice daily and 500 mg twice daily, respectively; each patient was given a 10-day supply of medication. Clinical success (cured or improved) was observed in 111 (96.5%) of 115 and in 108(93.9%) of 115 clinically-evaluable patients treated with clarithromycin and erythromycin, respectively. Eradication of the pathogen occurred in 108 (97.3%) of 111 and in 98 (92.5%) of 106 bacteriologically-evaluable clarithromycin and erythromycin patients, respectively. Adverse events reported by 7 (5.8%) of the clarithromycin-treated and by 12 (10%) of the erythromyc in-treated patients included epigastritis and nausea and vomiting. In general, the severity of adverse even...Keywords
This publication has 12 references indexed in Scilit:
- Selective killing of human T cell lymphotropic virus type I-transformed cell lines by a damavaricin Fc derivative.The Journal of Antibiotics, 1989
- In vitro immunosuppressive properties of spergualins to murine T cell response.The Journal of Antibiotics, 1989
- An in-vitro evaluation of the cellular uptake and infraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agentJournal of Antimicrobial Chemotherapy, 1988
- Comparative in vitro activities of new 14-, 15-, and 16-membered macrolidesAntimicrobial Agents and Chemotherapy, 1988
- Comparative in vitro activity of A-56268 against respiratory tract pathogensEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- The macrolide revival: Thirty five years after erythromycinAntimicrobic Newsletter, 1987
- In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1987
- Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycinAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntimicrobial Agents and Chemotherapy, 1986